<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002809</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064937</org_study_id>
    <secondary_id>TUHSC-2803</secondary_id>
    <secondary_id>NCI-V96-0950</secondary_id>
    <nct_id>NCT00002809</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Temple University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer&#xD;
      cells. Combining chemotherapy and radiation therapy together with bone marrow transplant may&#xD;
      allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bone marrow transplant from an&#xD;
      unrelated donor together with cyclophosphamide and total-body irradiation works in treating&#xD;
      patients with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Study the curative potential of high-dose cyclophosphamide and total-body irradiation&#xD;
           followed by rescue with bone marrow from volunteer HLA-matched donors in patients with a&#xD;
           variety of hematologic malignancies and bone marrow failure states.&#xD;
&#xD;
        -  Study the toxic effects associated with matched unrelated bone marrow transplantation in&#xD;
           this patient population.&#xD;
&#xD;
        -  Participate in collaborative research studies with the National Marrow Donor Program.&#xD;
&#xD;
      OUTLINE: All patients receive myeloablative therapy with high-dose cyclophosphamide and total&#xD;
      body irradiation over 4 days; patients with severe aplastic anemia also receive antithymocyte&#xD;
      globulin. Patients then undergo allogeneic bone marrow transplantation. Filgrastim (G-CSF) is&#xD;
      given after transplant to accelerate engraftment. Sargramostim (GM-CSF) may be given in case&#xD;
      of graft failure.&#xD;
&#xD;
      All patients receive graft-versus-host-disease (GVHD) prophylaxis with tacrolimus,&#xD;
      methotrexate, and gamma globulin. Established GVHD is treated with corticosteroids and, as&#xD;
      necessary, antithymocyte globulin.&#xD;
&#xD;
      Patients are followed at 100 days, 6 months, and 1 year after transplant, then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients per year will be accrued for this study over 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic immune globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following hematologic malignancies/disorders:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
                    -  In second or subsequent complete remission (CR)&#xD;
&#xD;
                    -  In first CR with high-risk features (e.g., Philadelphia chromosome-positive)&#xD;
&#xD;
                    -  In first relapse and failed conventional salvage therapy&#xD;
&#xD;
               -  Acute myelogenous leukemia (AML)&#xD;
&#xD;
                    -  In second or subsequent CR&#xD;
&#xD;
                    -  In early first relapse&#xD;
&#xD;
                    -  In full first relapse and failed conventional salvage therapy&#xD;
&#xD;
                    -  In first CR with high-risk features, e.g., trisomy 8 or FAB 6/7&#xD;
&#xD;
                         -  Standard-risk AML offered conventional-dose consolidation chemotherapy&#xD;
                            or autologous bone marrow transplantation&#xD;
&#xD;
               -  Chronic myelogenous leukemia in chronic, accelerated, or second chronic phase&#xD;
&#xD;
                    -  No blast crisis&#xD;
&#xD;
               -  Severe aplastic anemia that has failed at least 1 course of immunosuppressive&#xD;
                  therapy&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria with high-risk features (e.g., disseminated&#xD;
                  intravascular coagulation, thrombotic events)&#xD;
&#xD;
               -  Myelodysplastic syndrome, i.e.:&#xD;
&#xD;
                    -  Symptomatic, transfusion-dependent refractory anemia with excess blasts&#xD;
&#xD;
                    -  (RAEB) or RAEB in transformation&#xD;
&#xD;
               -  Secondary leukemia in CR following conventional-dose induction chemotherapy&#xD;
&#xD;
          -  Unrelated marrow donor available who is 8 out of 10-, 9 out of 10-, or 10 out of&#xD;
             10-antigen serologically HLA-matched at A, B, C, DRb, and DQB loci by molecular typing&#xD;
&#xD;
          -  No CNS malignancy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  17 to 60&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  No reduction due to other serious illness&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 3 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than twice normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 45%&#xD;
&#xD;
          -  No severe hypertension&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO, FEV_1, and FVC at least 50%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection at time of transplant&#xD;
&#xD;
          -  No advanced diabetes&#xD;
&#xD;
          -  No significant neurologic deficit&#xD;
&#xD;
          -  No active drug or substance abuse&#xD;
&#xD;
          -  No emotional disorders&#xD;
&#xD;
          -  Able to participate in frequent medical care for at least 1-2 years&#xD;
&#xD;
          -  Willing to comply with National Marrow Donor Program policies&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth F. Mangan, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase-Temple Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 30, 2010</last_update_submitted>
  <last_update_submitted_qc>September 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Temple University Bone Marrow Transplant Program</name_title>
    <organization>Temple University Health Systems</organization>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

